share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外國發行人報告（業績相關）
美股SEC公告 ·  2024/11/01 05:01

Moomoo AI 已提取核心訊息

NeuroSense Therapeutics has entered into a Standby Equity Purchase Agreement with YA II PN, LTD. (Yorkville) on October 31, 2024, securing access to up to $30 million in equity financing. The agreement grants the company the right to sell ordinary shares to Yorkville over a 36-month period at a 3% discount to the lowest three-day VWAP.The company will issue 224,697 ordinary shares to Yorkville as commitment shares and pay a $25,000 structuring fee. The purchase agreement includes restrictions limiting Yorkville's beneficial ownership to 4.99% of outstanding voting shares. The financing arrangement is subject to SEC registration requirements and customary closing conditions.Implementation of the agreement requires filing and SEC approval of a registration statement covering both commitment shares and future advance shares. The shares are being offered under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, with Yorkville representing as an accredited investor purchasing for investment purposes.
NeuroSense Therapeutics has entered into a Standby Equity Purchase Agreement with YA II PN, LTD. (Yorkville) on October 31, 2024, securing access to up to $30 million in equity financing. The agreement grants the company the right to sell ordinary shares to Yorkville over a 36-month period at a 3% discount to the lowest three-day VWAP.The company will issue 224,697 ordinary shares to Yorkville as commitment shares and pay a $25,000 structuring fee. The purchase agreement includes restrictions limiting Yorkville's beneficial ownership to 4.99% of outstanding voting shares. The financing arrangement is subject to SEC registration requirements and customary closing conditions.Implementation of the agreement requires filing and SEC approval of a registration statement covering both commitment shares and future advance shares. The shares are being offered under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, with Yorkville representing as an accredited investor purchasing for investment purposes.
NeuroSense Therapeutics 於2024年10月31日與 YA II PN, LTD. (Yorkville) 簽署了一份備用股權購買協議，確保獲得高達3000萬美元的股權融資。該協議賦予公司在36個月內以最低三日VWAP的3%折扣向Yorkville出售普通股的權利。公司將向Yorkville發行224,697股普通股作爲承諾股，並支付25000美元的結構費用。購買協議包括限制條款，限制Yorkville的有利所有權不超過4.99%的未償還投票股。該融資安排鬚遵循SEC註冊要求和慣例成交條件。實施該協議需要提交併獲得SEC對包括承諾股和未來預付款股的註冊聲明的批准。這些股份在證券法第4(a)(2)節和監管D第506條下發售，Yorkville作爲合格投資者，代表其購買用於投資目的。
NeuroSense Therapeutics 於2024年10月31日與 YA II PN, LTD. (Yorkville) 簽署了一份備用股權購買協議，確保獲得高達3000萬美元的股權融資。該協議賦予公司在36個月內以最低三日VWAP的3%折扣向Yorkville出售普通股的權利。公司將向Yorkville發行224,697股普通股作爲承諾股，並支付25000美元的結構費用。購買協議包括限制條款，限制Yorkville的有利所有權不超過4.99%的未償還投票股。該融資安排鬚遵循SEC註冊要求和慣例成交條件。實施該協議需要提交併獲得SEC對包括承諾股和未來預付款股的註冊聲明的批准。這些股份在證券法第4(a)(2)節和監管D第506條下發售，Yorkville作爲合格投資者，代表其購買用於投資目的。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Corcept醫療
    CORT
    -- 103.450
    bluebird bio
    BLUE
    -- 5.221
    Citius Pharmaceuticals
    CTXR
    -- 1.8593
    NLS Pharmaceutics
    NLSP
    -- 1.4900
    ABVC BioPharma
    ABVC
    -- 0.9703
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點